These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36974352)

  • 21. Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
    Wadwa RP; Laffel LM; Franco DR; Dellva MA; Knights AW; Pollom RK
    Diabetes Obes Metab; 2023 Jan; 25(1):89-97. PubMed ID: 36054737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
    Heise T; Piras de Oliveira C; Juneja R; Ribeiro A; Chigutsa F; Blevins T
    Diabetes Obes Metab; 2022 Sep; 24(9):1689-1701. PubMed ID: 35593434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study.
    Zhang Q; Chigutsa F; Chang AM
    Diabetes Ther; 2022 Aug; 13(8):1547-1557. PubMed ID: 35781789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial].
    Chen S; Zhou J; Lu JY; Bao YQ; Xu JW; Zhu JK; Jia WP
    Zhonghua Nei Ke Za Zhi; 2023 Sep; 62(9):1093-1101. PubMed ID: 37650183
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
    Leohr JK; Dellva MA; LaBell E; Coutant DE; Linnebjerg H
    Clin Ther; 2022 Jun; 44(6):836-847. PubMed ID: 35577602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
    Bergenstal RM; Bode BW; Bhargava A; Wang Q; Knights AW; Chang AM
    Diabetes Ther; 2023 Nov; 14(11):1933-1945. PubMed ID: 37740871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog
    Miura J; Imori M; Nishiyama H; Imaoka T
    Diabetes Ther; 2020 Sep; 11(9):2089-2104. PubMed ID: 32728832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes.
    Haliloglu B; Boughton CK; Lakshman R; Ware J; Nwokolo M; Thabit H; Mader JK; Bally L; Leelarathna L; Wilinska ME; Allen JM; Hartnell S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2024 Jul; 26(7):449-456. PubMed ID: 38315506
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness of postprandial Humalog in toddlers with diabetes.
    Rutledge KS; Chase HP; Klingensmith GJ; Walravens PA; Slover RH; Garg SK
    Pediatrics; 1997 Dec; 100(6):968-72. PubMed ID: 9374566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
    Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
    Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus.
    Garg SK; Anderson JH; Perry SV; Mackenzie T; Keith P; Jennings MK; Hansen MM; Chase HP
    Diabet Med; 1999 May; 16(5):384-7. PubMed ID: 10342337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Humalog® 200 U/ml KwikPen™].
    Scheen AJ
    Rev Med Liege; 2015 Oct; 70(10):527-31. PubMed ID: 26727843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.